Evaluation of D1/D5 Partial Agonist PF-06412562 in Parkinson's Disease following Oral Administration.

Evaluation of D1/D5 Partial Agonist PF-06412562 in Parkinson's Disease following Oral Administration. Neurodegener Dis. 2018 Nov 19;18(5-6):262-269 Authors: Papapetropoulos S, Liu W, Duvvuri S, Thayer K, Gray DL Abstract BACKGROUND: PF-06412562 is a moderately potent, highly selective oral D1/D5 dopamine receptor partial agonist. OBJECTIVE: To study the efficacy and safety of a single, oral, split dose of PF-06412562 in patients with Parkinson's disease. METHODS: Following overnight levodopa (L-dopa, Sinemet®) washout, subjects received a single dose of levodopa in open-label period 1. Periods 2 and 3 had a double-blinded, sponsor-open, randomized, 2-way cross-over, placebo-controlled design, during which subjects were randomized to PF-06412562 30 mg (+ 20 mg 4 h later) or placebo. Maximum percent improvement from baseline in finger-tapping speed (measure of bradykinesia) measured using KinesiaTM technology (as the primary end point) and change from baseline in the Movement Disorder Society's Unified Parkinson's Disease Rating Scale Part III (MDS-UPDRS-III) motor section scores (the preferred exploratory end point) were evaluated. RESULTS: Nineteen subjects received levodopa; 13 met the period 2/3 entry criteria and received PF-06412562, 30 + 20 mg, or placebo. The prespecified primary efficacy criterion for significant improvement in finger-tapping was not met due to inconsistencies in the task leading to large between-period fluctuat...
Source: Neuro-Degenerative Diseases - Category: Neurology Authors: Tags: Neurodegener Dis Source Type: research

Related Links:

Conclusion The patients in the DAT-positive group might have prodromal symptoms that were worsened by neuroleptic drugs. The results of detailed history-taking and neurological findings seem to indicate cases of compromised dopaminergic transmission before the administration of neuroleptic drugs. PMID: 32062624 [PubMed - in process]
Source: Internal Medicine - Category: Internal Medicine Tags: Intern Med Source Type: research
Conclusion: More data concerning the safety of antiparkinsonian drugs in PD treatment, as well as the effect of pregnancy on parkinsonian symptoms are needed. According to the current state of the art, L-DOPA therapy should be considered preferable to other drugs during pregnancy.
Source: Frontiers in Neurology - Category: Neurology Source Type: research
Condition:   Parkinson Disease Intervention:   Device: Auditive cueing Sponsors:   Ceriter Nederland BV;   Ziekenhuis Oost Limburg (ZOL) Hospital Genk, Belgium Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Parkinson Disease Intervention:   Drug: Lithium Sponsor:   University at Buffalo Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Parkinson Disease;   Cognitive Impairment, Mild;   Speech Interventions:   Diagnostic Test: Cognitive Battery;   Behavioral: Voice, Speech and Language Analysis;   Behavioral: Questionnaires and Clinical Assessments;   Genetic: DNA Analysis Sponsors:   University of Massachusetts, Worcester;   Sonde Health, Inc.;   Massachusetts Institute of Technology/Lincoln Labs;   Boston University;   VA Puget Sound Health Care System Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Parkinson Disease Intervention:   Drug: Lithium Sponsor:   University at Buffalo Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Parkinson Disease;   Cognitive Impairment, Mild;   Speech Interventions:   Diagnostic Test: Cognitive Battery;   Behavioral: Voice, Speech and Language Analysis;   Behavioral: Questionnaires and Clinical Assessments;   Genetic: DNA Analysis Sponsors:   University of Massachusetts, Worcester;   Sonde Health, Inc.;   Massachusetts Institute of Technology/Lincoln Labs;   Boston University;   VA Puget Sound Health Care System Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Parkinson Disease Intervention:   Device: Auditive cueing Sponsors:   Ceriter Nederland BV;   Ziekenhuis Oost Limburg (ZOL) Hospital Genk, Belgium Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Publication date: Available online 17 February 2020Source: Neuroscience &Biobehavioral ReviewsAuthor(s): Zhike Zhou, Yifan Liang, Xiaoqian Zhang, Junjie Xu, Jueying Lin, Rongwei Zhang, Kexin Kang, Huiling Qu, Chuansheng Zhao, Mei ZhaoAbstractBackgroundThe aim of this meta-analysis is to evaluate the association of fibrinogen with risk of dementia and its subtypes.MethodsEmbase, Pubmed and Web of Science were retrieved systematically up to February 2019. Standard mean difference (SMD) with 95% confidence intervals was estimated using random-effects models.ResultsSixteen studies involving 3,649 participants were summariz...
Source: Neuroscience and Biobehavioral Reviews - Category: Neuroscience Source Type: research
For a variety of sporadic neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis, it is well-established that ethnicity do affect the disease phenotypes. However, how the ethnicity could contribute to the clinical symptoms and disease progressions in monogenetic disorders, such as spinocerebellar ataxia type 3 (SCA3), remains less studied.
Source: Parkinsonism and Related Disorders - Category: Neurology Authors: Source Type: research
More News: Brain | Carbidopa/Levodopa | Cardiology | Cardiovascular | Heart | Neurology | Parkinson's Disease | Study | Switzerland Health